14.01.2020 • NewsElaine BurridgeShellCNOOC

Shell and CNOOC Plan PC Plant

Shell and CNOOC Plan PC Plant (c) Shell
Shell and CNOOC Plan PC Plant (c) Shell

Shell has signed a Memorandum of Understanding with CNOOC Oil & Petrochemicals to explore building a polycarbonate (PC) plant in China. The facility using Shell’s newly developed technology, which the company currently intends to further test and improve, would be located at the companies’ joint venture complex in Huizhou.

For Shell, it would be the first commercial-scale PC plant. To this end, the oil and energy group has already started building a development facility at its site on Jurong Island, Singapore, as an interim step with start-up said to be scheduled for 2021.

The oil and petrochemicals group is leveraging its patented diphenyl carbonate (DPC) process technology as the platform for a move into PC production. Shell said it has developed its DPC process over recent years to achieve significant advantages in cost, safety, efficiency and CO2 footprint. It will now combine this process with melt-phase phosgene-free PC technology licensed from Germany’s EPC Engineering & Technologies.

Shell’s PC plants would also produce alkylcarbonates, key components in the production of lithium ion batteries, which are seeing rising demand, particularly from the shift to electric vehicles.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.